Cardio-Oncology Spotlight: BTK Inhibitors and the Heart

Jeff Sharman M.D. is the medical director of hematology research for the US Oncology / Sarah Cannon Research Institute network. This consortium manages approximately one out of every five cancer patients treated in the United States and is the largest private research network in the country.  Dr Sharman developed the original idea of using BTK inhibitors to treat lymphoid malignancies and conducted the first in human studies of ibrutinib within his private practice at the Willamette Valley Cancer and Research Center in Eugene, Oregon, US.  Here Dr. Sharman addresses hypertension and arrhythmias related to BTK inhibitors.